Abstract: This disclosure relates to bivalent compounds (e.g., bi-functional small molecule compounds), compositions comprising one or more of the bivalent compounds, and to methods of use the bivalent compounds for the treatment of certain disease in a subject in need thereof. The disclosure also relates to methods for identifying such bivalent compounds.

Abstract: Provided are a vibration object monitoring method and apparatus, a computer device, and a storage medium. The method includes: in response to detecting that a vibration object exists in a monitoring video picture for a target monitoring region, a vibration object region in the monitoring video picture is determined, where the vibration object region is a region where the vibration object is located in the monitoring video picture; displacement information of a key point of the vibration object in the vibration object region is recorded; vibration information of the vibration object in the monitoring video picture is determined based on the displacement information; and a vibration object monitoring result for the target monitoring region is generated according to the vibration information. The abnormal vibration monitoring can be performed on the vibration object in the target monitoring region in time according to this method.

Abstract: Disclosed are a polyethylene glycol conjugate drug, and a preparation method therefor and the use thereof. Specifically, the present invention relates to a polyethylene glycol conjugate drug represented by formula A or a pharmaceutically acceptable salt thereof, a method for preparing the polyethylene glycol conjugate drug or the pharmaceutically acceptable salt thereof, an intermediate for preparing the polyethylene glycol conjugate drug or the pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the polyethylene glycol conjugate drug or the pharmaceutically acceptable salt thereof, and the use of the polyethylene glycol conjugate drug or the pharmaceutically acceptable salt thereof in the preparation of a drug.

Abstract: Provided are bivalent compounds (e.g., bi-functional small molecule compounds), compositions comprising one or more of the bivalent compounds, and methods of use the bivalent compounds for the treatment of certain disease in a subject in need thereof, and methods for identifying such bivalent compounds.

Abstract: Provided herein are compounds, pharmaceutical compositions, and methods for binding or degrading target proteins. Further provided herein are compounds having a DNA damage-binding protein 1 (DDB1) binding moiety. Some such embodiments include a linker. Some such embodiments include a target protein binding moiety. Further provided herein are ligand-DDB1 complexes. Further provided herein are in vivo modified DDB1 proteins.

Abstract: This disclosure relates to heterobifunctional compounds (e.g., bi-functional small molecule compounds), compositions comprising one or more of the heterobifunctional compounds, and to methods of use the heterobifunctional compounds for the treatment of certain disease in a subject in need thereof. The disclosure also relates to methods for identifying such heterobifunctional compounds.

Abstract: This disclosure relates to GSPT1 degrader compounds (e.g. small molecule compounds), compositions comprising one or more of the compounds, and to methods of use the compounds for the treatment of certain disease in a subject in need thereof. The disclosure also relates to methods for identifying such compounds.

Abstract: A display panel includes a substrate, a plurality of light-emitting devices, a first encapsulation layer, and a first dielectric layer. The first encapsulation layer includes a first portion and a second portion at least partially surrounding the first portion. The first dielectric layer is located between the first encapsulation layer and the plurality of light-emitting devices. Along the direction perpendicular to the plane of the display panel, a distance between a surface of the first portion away from at least one light-emitting device of the plurality of light emitting devices and a surface of the third portion away from the at least one light-emitting device is smaller than a distance between a surface of the second portion away from the at least one light-emitting device and a surface of the fourth portion away from the at least one light-emitting device.

Abstract: This disclosure relates to bivalent compounds (e.g., bi-functional small molecule compounds), compositions comprising one or more of the bivalent compounds, and to methods of use the bivalent compounds for the treatment of certain disease in a subject in need thereof. The disclosure also relates to methods for identifying such bivalent compounds.

Abstract: A generating device of simulating a particulate environment for an experimental animal includes an experimental chamber. An ultrasonic atomization device is installed at the bottom adjacent to the center of the experimental chamber. The upper side of the ultrasonic atomization device is connected to a guide device for guiding particles. The guide device includes an air seal cover, and a micro fan is installed inside the air seal cover to drive the movement of particles generated in the ultrasonic atomization device. Air guide pipes are fixedly connected to a side wall of the air seal cover. The generating device has good sealing performance, and can generate a variety of particle simulation environments to accurately and effectively simulate the biological effect of particles in the animal body. The generating device can improve the particle simulation environment, reduce the deviation of experimental data, and ensure the accuracy of the overall experimental data.

Abstract: This disclosure relates to heterobifunctional compounds (e.g., bi-functional small molecule compounds), compositions comprising one or more of the heterobifunctional compounds, and to methods of use the heterobifunctional compounds for the treatment of certain disease in a subject in need thereof. The disclosure also relates to methods for identifying such heterobifunctional compounds.

Abstract: Bivalent compounds composition comprises one or more of the bivalent compounds. The bivalent compound comprises a cyclic-AMP response element binding protein (CBP) and/or adenoviral EA binding protein of 300 kDa (P300) ligand (CBP/P3000 ligand) conjugated to a degradation tag. The method of using the bivalent compounds is treating certain disease in a subject in need thereof. The method of identifying such bivalent compounds is disclosed.

Abstract: Provided herein are compounds, pharmaceutical compositions, and methods for binding or degrading target proteins. Further provided herein are compounds having a DNA damage-binding protein 1 (DDB1) binding moiety. Some such embodiments include a linker. Some such embodiments include a target protein binding moiety. Further provided herein are ligand-DDB1 complexes. Further provided herein are in vivo modified DDB1 proteins.

Abstract: According to an example, key splitting may include utilizing a masked version of a master key that is masked by using a mask.

Abstract: The display panel includes a display region, where at least a portion of the display region is a transparent display region including a plurality of sub-regions, where the plurality of sub-regions are arranged in an array and have the same shape and the same area. A sub-region of the plurality of sub-regions includes a first side and a second side which are adjacent to each other. The sub-region includes a non-light-transmissive region and a light-transmissive region. A distance between a center of the light-transmissive region and a first side of a sub-region where the light-transmissive region is located is d1, a distance between the center of the light-transmissive region and a second side of the sub-region where the light-transmissive region is located is d2, and at least two of the plurality of sub-regions have at least one of different d1 or different d2.

Abstract: Bivalent compounds, compositions comprising one or more of the bivalent compounds, and methods of use the bivalent compounds for the treatment of certain disease in a subject in need thereof are provided. Methods for identifying such bivalent compounds are provided, either.

Abstract: This disclosure relates to bivalent compounds (e.g., bi-functional small molecule compounds), compositions comprising one or more of the bivalent compounds, and to methods of use the bivalent compounds for the treatment of certain disease in a subject in need thereof. The disclosure also relates to methods for identifying such bivalent compounds.

Abstract: Examples disclosed herein relate to data objects associated with private set intersection (PSI). Some examples disclosed herein may enable identifying a set of server elements and a set of data objects. Each data object of the set of data objects may be associated with at least one server element of the set of server elements. Some examples further enable sending the set of server elements and the set of data objects to a client computing device that has a set of client elements. A private set intersection (PSI) between the set of server elements and the set of client elements may be inaccessible by the client computing device, and a subset of the set of data objects that are associated with the PSI may be accessible by the client computing device.

Abstract: In one example in accordance with the present disclosure, a method may receiving a plaintext to be encrypted. The plaintext may include a first block, a second block and a third block. The method may include generating a preliminary ciphertext based on the first block and the second block and generating, using an encryption key, a first ciphertext using an encryption operation receiving the third block and the preliminary ciphertext as inputs. The method may also include generating, using the encryption key, a first finalized ciphertext using the encryption operation receiving the first block and the first ciphertext as inputs and generating, using the encryption key, a second finalized ciphertext using the encryption operation receiving the second block and the first finalized ciphertext as inputs.

Abstract: The present invention discloses a molecular detection kit for SARS-CoV-2 virus including 2× RT-qPCR mix, upstream primer detF, downstream primer detR, probe, positive control, negative control. The kit has good detection specificity and stability, high sensitivity, and strong anti-interference ability for nucleic acid from the virus host. It has the advantages of simple operation and short time consumption. Moreover, the preparation of positive control is convenient and the cost is low. It can be widely used in early screening of SARS-CoV-2 virus, as well as for epidemic control, scientific research and other fields.